JLE

Epileptic Disorders

MENU

Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine Volume 13, issue 4, December 2011

Aires CC, Soveral G, Luís PB, et al. Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes. FEBS Lett 2008 ; 582 : 3359-3366.

Castro-Gago M, Eirís-Puñal J, Novo-Rodríguez MI, Couceiro J, Camiña F, Rodríguez-Segade S. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol 1998 ; 13 : 546-549.

Chace DH, Hillman SL, Van Hove JL, Naylor E.W. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997 ; 43 : 2106-2113.

Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989 ; 30 : 389-399.

Coppola G, Epifanio G, Auricchio G, Federico RR, Resicato G, Pascotto A. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev 2006 ; 28 : 358-365.

Coulter D.L. Carnitine, valproate, and toxicity. J Child Neurol 1991 ; 6 : 7-14.

Coulter D.L. Carnitine deficiency in epilepsy: Risk factors and treatment. J Child Neurol 1995 ; 10 : S32-S39.

Fung EL, Tang NL, Ho CS, Lam CW, Fok T.F. Carnitine level in Chinese epileptic patients taking sodium valproate. Pediatr Neurol 2003 ; 28 : 24-27.

Haas R, Stumpf DA, Parks JK, Eguren L. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981 ; 31 : 1473-1476.

Hamed SA, Abdella M.M. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Epilepsy Res 2009 ; 86 : 32-41.

Hirose S, Mitsudome A, Yasumoto S, Ogawa A, Muta Y, Tomoda Y. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998 ; 101 : E9.

Hug G, McGraw CA, Bates SR, Landrigan E.A. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991 ; 119 : 799-802.

Kurul S, Dirik E, Iscan A. Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy. J Child Neurol 2003 ; 18 : 552-554.

2009 ; Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 47 : 101-111.

Luís PB, Ruiter JP, Aires CC, et al. Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation. Biochim Biophys Acta 2007 ; 1767 : 1126-1133.

McFarland R, Hudson G, Taylor RW, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase γ (POLG1). BMJ Case Rep 2009; 2009. pii: bcr12.2008. 1303.

Opala G, Winter S, Vance C, Vance H, Hutchison HT, Linn L.S. The effect of valproic acid on plasma carnitine levels. Am J Dis Child 1991 ; 145 : 999-1001.

Price KE, Pearce RE, Garg UC, et al. Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clin Pharmacol Ther 2011 ; 89 : 867-874.

Riva R, Albani F, Gobbi G, Santucci M, Baruzzi A. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia 1993 ; 34 : 184-187.

Rumbach L, Warter JM, Rendon A, Marescaux C, Micheletti G, Waksman A. Inhibition of oxidative phosphorylation in hepatic and cerebral mitochondria of sodium valproate-treated rats. J Neurol Sci 1983 ; 61 : 417-423.

Saudubray JM, Martin D, de Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 1999 ; 22 : 488-502.

Scheuer ML, Pedley T.A. The evaluation and treatment of seizures. N Engl J Med 1990 ; 323 : 1468-1474.

Silva MF, Jakobs C, Duran M, de Almeida IT, Wanders R.J. Valproate induces in vitro accumulation of long-chain fatty acylcarnitines. Mol Genet Metab 2001a ; 73 : 358-361.

Silva MF, Selhorst J, Overmars H, et al. Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. Clin Biochem 2001b ; 34 : 635-638.

Silva MF, Aires CC, Luis PB, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review. J Inherit Metab Dis 2008 ; 31 : 205-216.

Stanley C.A. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004 ; 1033 : 42-51.

Thom H, Carter PE, Cole GF, Stevenson K.L. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol 1991 ; 33 : 795-802.

Van Wouwe J.P. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 1995 ; 65 : 211-214.

Werner T, Treiss I, Kohlmueller D, et al. Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. Epilepsia 2007 ; 48 : 72-76.

Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence?. Acta Paediatr 1995 ; 84 : 93-95.

Zelnik N, Isler N, Goez H, Shiffer M, David M, Shahar E. Vigabatrin, lamotrigine, topiramate and serum carnitine levels. Pediatr Neurol 2008 ; 39 : 18-21.

Ziadeh R, Hoffman EP, Finegold DN, et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995 ; 37 : 675-678.